While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

The company projects mid to high single-digit sales growth in 2025 at constant exchange rates, excluding hyperinflation effects, and low double-digit business EPS growth before foreign exchange and ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...

Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, with health experts warning ...

The transaction would allow Sanofi to solely focus on its more lucrative, drugs and vaccines business. The company's research-and-development spending increased 24% on-year in the last quarter in an ...